3 Toxicity in blcloaical systems (a) imitating uraemic symptoms in animals, with enzymes or cells (b) concentrations occuring in uraemic patients 4 Specific and quantitive measurements Table 2 Requirements for acknowledgment of a compound as a uraemic toxin neum is more permeable to larger molecules than dialysis membranes because it has a higher membrane diffusion resistance.
In accordance with that finding was the observation that, in contrast to urea and creatinine, the removal rates of solutes with a molecular weight of at least that of vitamin B12 is virtually independent of both dialysate and blood flow rates but depends on the membrane surface area and the dialysis time (Jebsen et al., 1967; Christopher et al., 1971; Ginn et al., 1971) . These results lead to the square-metre-hour-hypothesis and later to the middle molecule hypothesis (Babb et al., 1971; 1972) . According to these hypotheses, the wellbeing of uraemic patients can be improved both by increasing the surface area of the dialyser and by the prolongation of treatment time since both manipulations favour the elimination of solutes with a molecular weight comparable to that of vitamin B12 or higher. Later, the term 'middle molecules' was extended to solutes with a molecular weight between 500 and 5000 daltons, indicating that there might exist even larger uraemic retention products whose role as uraemic toxins, however, is assumed to be of little importance because they cannot be eliminated through ordinary dialysis membranes.
Passage through the dialysis membrane is an essential requirement in acknowledging a solute as a uraemic toxin as long as the improvement in the clinical condition of uraemic patients during haemodialysis is attributed to the removal of toxic compounds.
To consider a compound as a uraemic toxin is justified if the following conditions at least are fulfilled ( Table 2) Recently, interest has been focused on the question whether larger solutes play a role as uraemic toxins. This consideration is based on the observation that patients on long-term peritoneal dialysis develop uraemic polyneuropathy to a lesser degree than haernodialysis patients despite a lower efficiency of the former with regard to the elimination of known retention products such as urea and creatinine (Teuckhoff and Curtis, 1970) .
To explain this phenomenon it was assumed that uraemic polyneuropathy is caused by the accumulation of larger compounds which can be eliminated more easily by peritoneal dialysis than by haemodialysis (Scribner, 1965) due to the larger pore size of the peritoneal membrane. In fact, later it was demonstrated (Babb et 01., 1973) The term uraemia was introduced by Piorry and L'Heritier in 1840 to describe the assumption that the syndrome is caused by the reabsorption of urine into the bloodstream. Today uraemia is acknowledged as an endogenous intoxication, compounds accumulating in renal failure due to impaired excretion and/or increased synthesis.
During the last decades numerous compounds have been accused of representing uraemic toxins (Bergstrom and Furst, 1978) (Table 1) . Nowadays it is widely accepted that the uraemia-specific manifestations affecting nearly all metabolic pathways and organ systems cannot be ascribed to a single toxin but that they are the result of the combined effects of many substances, the individual toxicity of which is still under investigation.
Determination of middle molecules
As early as 1938 Cristol et al. described the existence of small polypeptides in uraemic patients which could not be found in subjects with normal kidney function. The plasma concentration of that compound varied independently from other nitrogencontaining retention products. Using ion exchange chromatography, Desi et al. (1957) detected a small peptide in the plasma from uraemic patients not present in healthy subjects. Despite these earlier findings the search has been intensified for larger retention products after the development of the middle molecule hypothesis (Dzurik et al., 1971; Dall'Aglio et al., 1972) . The most sophisticated method to characterise uraemic middle molecules has been developed by FUrst and colleagues (FUrst et al., 1976; Bergstrom and FUrst, 1976; Zimmerman et al., 1979) using a combination of high-speed gelfiltration with subsequent gradient ion exchange chromatography and analytical isotachophoresis.
By gelfiltration on Sephadex G 15 and recording the OD at 206 nm, urine and ultrafiltrates from normal and uraemic plasma could be separated into 10 peaks, one of which, peak 7, was found in plasma and in urine from uraemic patients but was absent in plasma from healthy subjects (FUrst et al., 1976) .
Peak 7 could be further separated by gradient ion exchange chromatography into seven to eight subpeaks (7a, 7b, 7c . . . ) with a molecular weight range between 1000 and 2000 daltons (FUrst et al., 1976; Fust and Bergstrom, 1976) . Using analytical isotachophoresis, the subpeaks 7a, 7b, and 7c could be demonstrated each to consist of two very similar components (Zimmerman et al., 1979) .
As far as the chemical nature is concerned the presence of peptides could be demonstrated (Fiirst et al., 1976) . However, there appears to be no relation to known peptide hormones accumulating in renal failure.
Applying a different isolation procedure, Abiko et al. (1978) found a heptapeptide occurring exclusively in uraemic body fluids and corresponding completely to the heptapeptide moiety of portion 13 to 19 of Ih-microglobulin. Funck-Brentano et al. (1976) described a compound with a molecular weight of 1100-1300 daltons in the plasma and urine of uraemic patients, the concentration of which is closely related to the degree of polyneuropathy of the patients under investigation. Additionally, these fractions proved to be neurotoxic in the frog sural nerve test in vitro. Chemically, the neurotoxic fraction consists of four compounds, one of which is a peptide, On the other hand. a substance with a H. W. Leber, G. Goubeaud and Rita Spiegelhalter polyhydroxy acid structure (C12H44-46022-25N) could be isolated (Cueille et al., 1978) .
In conclusion, the accumulation of solutes within the middle molecular range predicted from manipulations of dialysis strategies has meanwhile been proved analytically. However, the solutes still lack adequate chemical characterisation.
Middle molecules as uraemic toxins CLINICAL STUDIES
It is, however, still questionable whether middle molecules are responsible for the uraemic syndrome in a cause and effect relationship. If this were the case one would expect the plasma concentration of middle molecules to be especially high in patients with a high degree of uraemia and/or that typical uraemic complications such as ployneuropathy, anaemia, and pericarditis could be related to high levels of certain middle molecular fractions. However, most attempts to correlate the plasma concentrations of middle molecules with clinical findings in the patients failed. This is due mainly to the fact that the isolation procedure for middle molecules usually resulted in a mixture of different solutes, each probably with different generation rates, elimination patterns, and optical properties. For such correlation studies it is essential to relate clinical findings to individual compounds. Other difficulties arise from the finding that the plasma concentration of single middle molecules isolated so far appears to depend on several factors apart from the degree of uraemia. Bergstrom et al. (1976) demonstrated, for instance, that the plasma concentration of peak 7c in individual dialysis patients was related to episodes of fever, malnutrition, and overhydration apparently independent of variations of the degree of uraemia.
Only recently, Funck-Brentano et al. (1976) claimed that the extent of polyneuropathy in uraemic patients is closely related to the plasma concentration of peak b4 according to their nomenclature.
Our own investigations indicated that uraemic middle molecules are not related to the degree of glucose intolerance or to polyneuropathy but might be loosely related to anaemia (Goubeaud et al., 1976; .
Summarising, until now the measurement of middle molecular solutes in uraemic patients has not revealed whether these compounds play a role in inducing the complications typical of the uraemic state. To solve this question finally more specific determination methods for single retention products within the middle molecular range are required. Another means of evaluating the toxicity of uraemic middle molecules could be the injection of the corresponding fractions into experimental animals to find out whether typical uraemic manifestations are induced. In fact, Bergstrom and FUrst (1978) observed a reduced in vivo s9Fe uptake in the bone marrow cells of normal mice during treatment with peak 7c, an effect that could be connected with insufficient haematopoiesis. However, systematic investigations concerning the effects of uraemic middle molecules in laboratory animals are lacking, as yet, mainly due to the fact that, in order to maintain sufficient plasma concentrations, large amounts of pure fractions are required as long as the kidney function of the animals is not impaired.
IN VITRO TOXICITY STUDIES
Despite all these difficulties, to evaluate the role of middle molecules in the uraemic syndrome, we investigated the toxicity of middle molecular fractions from uraemic patients at a cellular and enz-yme level in vitro (Goubeaud et al .• 1976; Leber et al., 1974 Leber et al., , 1975 .
For this purpose it was necessary to develop a preparatory isolation method for middle molecules because the available analytical methods did not yield enough material for subsequent toxicological studies. The principle of our method for the preparation of middle molecular samples is depicted in Fig. 1 ; details have been published in a foregoing paper (Leber et al., ) . It was the aim of our toxicological studies to find out whether typical uraemic manifestations could be induced in normal cells by adding middle molecules in vitro.
As model cells peripheral red blood cells from healthy subjects were investigated. The reason for this was the fact that we had found typical functional alterations in peripheral red blood cells from uraemic patients (Table 3) . We therefore investigated whether middle molecular fractions isolated from uraemic patients could produce similar disturbances when added to normal peripheral red blood cells in vitro. Table 4 depicts the influence of various uraemic Controt .. GSH~~""""""~""''''''~~~'--:-: ;"1 n = 5
Influence 01 GSH 15m moles 1/ ) and uremic middle molecules (from 5 mJ serum) on the actmty 01 ,,-ALA -0 in normal erytMoeyfes Fig.4 Influence of GSH(jillal concentration 5 mmolll) and uraemic middle molecules on the D-ALA-D activity of normal erythrocytes.
middle molecules isolated from patients suffering from acute liver failure do not affect the D-ALA-D activity (Leber et al., 0000) .
The fact that GSH stimulates D-ALA-D in both uraemic red blood cells (Leber et a/1979) and normal erythrocytes inhibited by the presence of uraemic middle molecules sustains the assumption that middle molecules from uraemic patients affect SH-groups which are essential for the D-ALA-D action (Finelli et al., 1975) .
Further investigations were designed to evaluate whether uraemic middle molecules are important factors in causing an increased rate of haemolysis, which is a common finding in uraemic patients. Earlier experiments from our group had revealed that erythrocytes from uraemic patients withdrawn before dialysis had higher haemolysis rates than those from healthy subjects when the incubation mixture contained hydrogen peroxide. After haemodialysis no difference could be detected between both groups of erythrocytes , thus ruling out the possibility that the increased haemolysis rate of erythrocytes from uraemic patients is caused by a difference in cell age. More likely it is due to a toxic factor which is removed during haemodialysis. Figure 5 demonstrates that the peroxide-induced haemolysis rate of normal erythrocytes can be significantly augmented by adding uraemic middle molecules in vitro . From this finding it is concluded that the middle molecules present in uraemic blood are-at least in partresponsible for the higher peroxidative haemolysis rate of uraemic erythrocytes. The exact mechanism underlying this observation remains as yet unknown. However, very recent results indicate that uraemic middle molecules inhibit the catalase-dependent Porphyrin synthesis Inhibition of D-A1.A-D Inhibition of PRC-lJ (b) Inhibition of globin synthesis '1 Increased peroxidurive haemulysis retention products and of middle molecular solutes isolated from the plasma of uraemic patients on globinsynthesis and on the activities of the enzymes delta-aminolevulinic acid dehydrase (D-ALA-D) and porphobilinogen desaminase (PBG-D) in peripheral red blood cells from healthy subjects (Goubeaud et al., 1976; Leber et al., 1974 .
PBG-D is not inhibited by any of the solutes investigated so far. The globinsynthesis is inhibited by the addition of uraemic middle molecules and by guanidine derivatives known to accumulate in renal failure. But to demonstrate the inhibiting effect of the latter substances concentrations are required which markedly exceed the plasma concentrations in uraemic patients. D-ALA-D is specifically inhibited in normal cells by uraemic middle molecules. Additional investigations have revealed that the inhibiting effect on D-ALA-D is not mediated by metal impurities such as Pb or Cd, which are known to depress the activity of that enzyme . On the other hand, the middle molecule dependent inhibition of D-ALA-D can be reversed by adding GSH to the incubation mixture (Fig. 4) . Additionally, the decreased D-ALA-D activity of uraemic peripheral red blood cells can be normalised if the assay system contains adequate amounts of GSH. Similar effects have been found when zinc instead of GSH was present (unpublished observation).
The mechanism by which uraemic middle molecules inhibit D-ALA-D is not yet clear. However, it appears to be a specific effect of uraemia, because % hemoly s i s 13hours Normal ery tbrocyres. Abiko, T., Kumikawa, M., Hiroki, H., and Sekino, H. (1978) . Identification and synthesis of a heptapeptide in uremic fluid. Biochemical and Biophysical Research Communications, 84, 184. Babb, A. L., Farrell, P. C., Uvelli, D. A., and Scribner, B. H. (1972) . Hemodialyzer evaluation by examination of solute molecular spectra. Transactions of the American Society for Artificial Internal Organs (Washington), 18,98. Babb, A. L., Johansen, P. J., Strand, M. J., Tenckhoff, H., and Scribner, B. H. (1973) Despite the uncertainty about the role of middle molecules as uraemic toxins the middle molecule hypothesis has been very stimulating with regard to dialyser technology and to new treatment strategies. New highly permeable membranes have been developed and large surface area dialysers have been used increasingly. Haemofiltration and haemoperfusion were introduced into the treatment of uraemic patients because both procedures favour the elimination of middle molecules compared to small solutes such as urea.
In future more specific determination methods should be applied in order to characterise middle molecules better than has been possible up to now. This is the main requirement finally to elucidate their role in uraemic patients. 
Glucokinase
It is not yet clear whether these effects are of any importance under in-vivo conditions. However, they sustain the assumption that individual middle molecular fractions accumulating in renal failure might hydrogen peroxide degradation in normal erythrocytes (unpublished), whereas other enzymes involved in the detoxification of oxygen radicals maintain normal or even higher activities in uraemic erythrocytes .
So far, our in-vitro experiments indicate that three functional alterations typical of uraemic erythrocytes can be imitated in normal erythrocytes by adding uraemic middle molecules (globinsynthesis, D-ALA-D, peroxidative haemolysis), Table 5 summarises the toxic effects that have been described by several authors (Bergstrom and Furst, 1978) after incubating normal cells or enzymes with uraemic middle molecules in vitro.
Fig. S Influence of different uraemic retention
products on peroxidative haemolysis of normal erythrocytes. MM, middle molecules containing gel filtrate fractions .. Fl , gel filtrate fractions containing solutes with a MW higher than 1500 daltons.
